• 1.

    Kahn SE, et al.. Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. Lancet 2014; 383:10681083.

  • 2.

    Andersen ES, et al.. Do we know the true mechanism of action of the DPP-4 inhibitors? Diabetes Obes Metab 2018; 20:3441.

  • 3.

    Davies MJ, et al.. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41:26692701.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Davidson JA. The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes. Endocr Pract 2013; 19:10501061.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Tkac I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care 2017; 40:284286.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Lee SG, et al.. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol 2019; 155:172177.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab 2016; 18:333347.

  • 8.

    Rosenstock J, et al.. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 2015; 38:376383.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Cooper ME, et al.. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis 2015; 66:441449.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Groop PH, et al.. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: The randomized MARLINA-T2D trial. Diabetes Obes Metab 2017; 19:16101619.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Rosenstock J, et al.. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial. JAMA 2019; 321:6979.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Marx N, et al.. Design and baseline characteristics of the CARdiovascular Outcome trial of LINAgliptin versus glimepiride in type 2 diabetes (CAROLINA®). Diab Vasc Dis Res 2015; 12:164174.

    • Crossref
    • Search Google Scholar
    • Export Citation

Dipeptidyl Peptidase-4 Inhibitors

  • 1 Muhammad Maqbool and Mark E. Cooper are with the Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.
Restricted access
Save